Acute Myeloid LeukemiaMYEL-CD180NCT07895901
Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
An observational study of Acute Myeloid Leukemia and Myeloid Hematological Malignancies, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML). Read more about this study
- Who is it for?
- Ages 1 year and older
- Conditions the study is for
- Acute Myeloid Leukemia, Myeloid Hematological Malignancies, Normal Hematopoietic Stem and Progenitor Cells
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 21 Jan 2026to 21 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with confirmed or suspected acute myeloid leukemia, or patients undergoing assessment of hematopoietic stem cells using blood or bone marrow samples, at Strasbourg University Hospitals.
Who may be able to join
- Adult patients aged 18 years or older.
- Pediatric patients aged 1 to 17 years.
- Patients with confirmed or suspected acute myeloid leukemia who have undergone bone marrow aspiration as part of the diagnostic or relapse assessment.
- Patients whose stem cells are being assessed using a blood or bone marrow sample.
- Patients and/or their legal representatives, where applicable, informed by letter of the use of residual sample material for research purposes.
- No written objection documented in the medical record to the reuse of personal data for scientific research.
Who cannot join
- Patients and/or their legal representatives, where applicable, who have objected to the reuse of personal data for scientific research.
- Samples more than 72 hours old.
- Clotted samples.
- Samples with insufficient volume (less than 10 microliters).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Laboratoire d'Hématologie Biologique - CHU de Strasbourg - France
Strasbourg, 67091
Laurent Mauvieux, MD, PhD, 33 3 88 12 75 27, laurent.mauvieux@chru-strasbourg.fr
Laurent Mauvieux, MD, PhD
About this study
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML).
This monocentric, non-interventional, retrospective observational study aims to characterize CD180 expression by flow cytometry in pathological hematopoietic cells, particularly in AML, and in normal hematopoietic stem and progenitor cells (CD34+ cells). The study will use residual blood and bone marrow samples collected during routine care and otherwise intended for disposal by incineration, together with relevant clinical and laboratory data.
- Conditions
- Acute Myeloid Leukemia, Myeloid Hematological Malignancies, Normal Hematopoietic Stem and Progenitor Cells
- Keywords
- CD180, Acute Myeloid Leukemia
- Medical subject headings
- Leukemia, Myeloid, Acute
What is being measured
The primary outcome is the main question the study is designed to answer.
CD180 Expression in Normal and Pathological CD34+ Cells
Percentage of CD34+ cells expressing CD180 above the levels observed in negative control populations (T lymphocytes and neutrophils), and intensity of CD180 expression measured by antibody-based fluorescence intensity.
Measured: During the 6-month data collection period, from January 21, 2026, to July 21, 2027.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2026
- Study start21 Jan 2026
- Primary completion21 Apr 2027 (estimated)
- Study completion21 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myeloid LeukemiaStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07895901
- Sponsor's protocol ID
- RC25_0072
- Acronym
- MYEL-CD180
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
- ClinicalTrials.gov ID
- NCT07895901
- Acronym / sponsor ID
- MYEL-CD180 / RC25_0072
- Conditions
- Acute Myeloid Leukemia, Myeloid Hematological Malignancies, Normal Hematopoietic Stem and Progenitor Cells
- Keywords
- CD180, Acute Myeloid Leukemia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 21 Jan 2026 (actual)
- Primary completion
- 21 Apr 2027 (estimated)
- Study completion
- 21 Jul 2027 (estimated)
- First posted
- 26 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML).
This monocentric, non-interventional, retrospective observational study aims to characterize CD180 expression by flow cytometry in pathological hematopoietic cells, particularly in AML, and in normal hematopoietic stem and progenitor cells (CD34+ cells). The study will use residual blood and bone marrow samples collected during routine care and otherwise intended for disposal by incineration, together with relevant clinical and laboratory data.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 1 year and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with confirmed or suspected acute myeloid leukemia, or patients undergoing assessment of hematopoietic stem cells using blood or bone marrow samples, at Strasbourg University Hospitals.
Key inclusion criteria (6 listed)
- Adult patients aged 18 years or older.
- Pediatric patients aged 1 to 17 years.
- Patients with confirmed or suspected acute myeloid leukemia who have undergone bone marrow aspiration as part of the diagnostic or relapse assessment.
- Patients whose stem cells are being assessed using a blood or bone marrow sample.
- Patients and/or their legal representatives, where applicable, informed by letter of the use of residual sample material for research purposes.
Key exclusion criteria (4 listed)
- Patients and/or their legal representatives, where applicable, who have objected to the reuse of personal data for scientific research.
- Samples more than 72 hours old.
- Clotted samples.
- Samples with insufficient volume (less than 10 microliters).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
CD180 Expression in Normal and Pathological CD34+ Cells
Time frame: During the 6-month data collection period, from January 21, 2026, to July 21, 2027.
Percentage of CD34+ cells expressing CD180 above the levels observed in negative control populations (T lymphocytes and neutrophils), and intensity of CD180 expression measured by antibody-based fluorescence intensity.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
Related trials for Acute Myeloid Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 1/2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myeloid Leukemia and Myeloid Hematological Malignancies, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laurent Mauvieux, MD, PhD (33 3 88 12 75 27, laurent.mauvieux@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CD180 Expression in Normal and Pathological CD34+ Cells (time frame: During the 6-month data collection period, from January 21, 2026, to July 21, 2027.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.